Skip to main content
OpenTrials
Completed

NCT Number: NCT00186355

Enrichment & Purging of Stem Cells in Non-Hodgkin's Lymphoma

To evaluate the role of purging the hematopoietic cell graft on outcomes for non-Hodgkin's Lymphoma.

Completed

Looking for future studies?

Notify Me

Key information

Age range

4 week–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stanford University School of Medicine

Stanford, California, 94305, United States

About this study

To study the use of peripheral blood stem cells which have been treated in an effort to remove tumor cells. The researchers hope to learn whether or not this will be more effective in removing the tumor cells as compared to other methods of purging (the removal of cancer cells).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

- relapsed NHL Exclusion Criteria:- liver dysfunction

Treatment and study plan

high dose chemo then auto hematopoietic cell transplant

Procedure

Primary outcomes

  1. PCR positivity in peripheral blood cell collections after cyclophosphamide

Secondary outcomes

  1. Enrichment of hematopoietic stem cells

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Collaborators

  • National Institutes of Health (NIH)

Registry information

Official study title

Enrichment and Purging of Stem Cells in the Treatment of Non-Hodgkin's Lymphoma

Important dates

Study start
2003
Primary completion
2007
Study completion
2010
First posted
Sep 16, 2005
Registry last updated
May 14, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.